Skip to main content
Erschienen in: Investigational New Drugs 4/2018

19.02.2018 | PRECLINICAL STUDIES

Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells

verfasst von: Jade K. Pollock, Lisa M. Greene, Seema M. Nathwani, Paula Kinsella, Niamh M. O’Boyle, Mary J. Meegan, Daniela M. Zisterer

Erschienen in: Investigational New Drugs | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Summary

Purpose The combretastatins (CAs) are known to exhibit anti-tumour activity but the underlying mechanism remains to be fully elucidated. Inflammation plays a critical role in altering the function of cancer cells and evasion of cell death and increased proliferation are characteristics of transformed malignancies. Many of the proteins involved in these pathways are regulated by the transcription factor NF-κB which can be activated by tumour necrosis factor (TNF-α), a pro-inflammatory cytokine released by both malignant and immune cells within the tumour microenvironment. In this study, we examined the ability of combretastatin A-4 (CA-4) and its novel, cis-restricted analogue CA-432 to target the NF-κB signalling pathway in T cells. Methods Effects of the CAs on the viability of DND-41 leukaemia and Jurkat lymphoma T-cell lines was assessed by the alamar blue assay. Induction of apoptosis and effects on expression levels of key apoptotic proteins was established though flow cytometry and western blotting. Modulation of the NF-κB signalling pathway was determined through western blotting and through assessment of NF-κB reporter gene activity. Results CA-4 and CA-432 reduced cell viability and induced apoptosis in DND-41 and Jurkat T cells and sensitised the cells to TNF-α-induced apoptosis through inhibition of the NF-κB signalling pathway. Suppression of the NF-κB pathway downregulated NF-κB–dependent gene products involved in cell survival (IAPs, Bcl-2 and Mcl-1), proliferation (cyclin D1) and inflammation (COX-2). Furthermore, both CA-4 and CA-432 inhibited TNF-α-induced NF-κB activation through the inhibition of IκBα degradation and p65 nuclear translocation and decreased NF-κB reporter gene activity. Conclusions Our data indicate that the anti-cancer properties of comebretastatins may be mediated in part through targeting the NF-κB pathway. This study provides new insights into the molecular mechanisms of CA compounds and a potential application of combretastatins for inflammatory diseases such as cancers, which are associated with abnormal NF-κB activation.
Literatur
1.
Zurück zum Zitat Nagaiah G, Remick SC (2010) Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol 6(8):1219–1228CrossRefPubMed Nagaiah G, Remick SC (2010) Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol 6(8):1219–1228CrossRefPubMed
2.
Zurück zum Zitat Nathwani SM et al (2013) Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro. Oncol Rep 29(2):585–594CrossRefPubMed Nathwani SM et al (2013) Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro. Oncol Rep 29(2):585–594CrossRefPubMed
3.
Zurück zum Zitat Greene LM et al (2010) The vascular targeting agent Combretastatin-A4 and a novel cis-restricted β-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. J Pharmacol Exp Ther 335(2):302–313CrossRefPubMed Greene LM et al (2010) The vascular targeting agent Combretastatin-A4 and a novel cis-restricted β-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. J Pharmacol Exp Ther 335(2):302–313CrossRefPubMed
4.
Zurück zum Zitat Greene LM et al (2012) The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells. Biochem Pharmacol 84(5):612–624CrossRefPubMed Greene LM et al (2012) The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells. Biochem Pharmacol 84(5):612–624CrossRefPubMed
5.
Zurück zum Zitat Pang Y et al (2015) Structure of the apoptosome: mechanistic insights into activation of an initiator caspase from drosophila. Genes Dev 29(3):277–287CrossRefPubMedPubMedCentral Pang Y et al (2015) Structure of the apoptosome: mechanistic insights into activation of an initiator caspase from drosophila. Genes Dev 29(3):277–287CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefPubMed Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefPubMed
7.
Zurück zum Zitat Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441(7092):431–436CrossRefPubMed Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441(7092):431–436CrossRefPubMed
8.
Zurück zum Zitat Hsu H et al (1996) TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4(4):387–396CrossRefPubMed Hsu H et al (1996) TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4(4):387–396CrossRefPubMed
9.
Zurück zum Zitat Pikarsky E et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461–466CrossRefPubMed Pikarsky E et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461–466CrossRefPubMed
11.
Zurück zum Zitat Carr M et al (2010) Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects. Eur J Med Chem 45(12):5752–5766CrossRefPubMed Carr M et al (2010) Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects. Eur J Med Chem 45(12):5752–5766CrossRefPubMed
12.
Zurück zum Zitat Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27–55CrossRef Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27–55CrossRef
13.
Zurück zum Zitat Lu W et al (2003) Active specific immunotherapy against occult brain metastasis. Cancer Res 63(6):1345–1350PubMed Lu W et al (2003) Active specific immunotherapy against occult brain metastasis. Cancer Res 63(6):1345–1350PubMed
14.
Zurück zum Zitat Nakamura Y et al (2013) Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERbeta) in human prostate cancer. Prostate 73(6):590–595CrossRefPubMed Nakamura Y et al (2013) Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERbeta) in human prostate cancer. Prostate 73(6):590–595CrossRefPubMed
16.
18.
Zurück zum Zitat Xu L, et al. (2014) COX-2 Inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med 6(242):242CrossRef Xu L, et al. (2014) COX-2 Inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med 6(242):242CrossRef
19.
Zurück zum Zitat Sung B, Ahn KS, Aggarwal BB (2010) Noscapine, a Benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappa B signaling pathway. Cancer Res 70(8):3259–3268CrossRefPubMedPubMedCentral Sung B, Ahn KS, Aggarwal BB (2010) Noscapine, a Benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappa B signaling pathway. Cancer Res 70(8):3259–3268CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Lennon JC et al (2014) The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells. Biochem Pharmacol 87(4):611–624CrossRefPubMed Lennon JC et al (2014) The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells. Biochem Pharmacol 87(4):611–624CrossRefPubMed
21.
Zurück zum Zitat Ling X et al (2004) Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G(2)/M arrest. J Biol Chem 279(15):15196–15203CrossRefPubMed Ling X et al (2004) Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G(2)/M arrest. J Biol Chem 279(15):15196–15203CrossRefPubMed
22.
Zurück zum Zitat Zeng W et al (2014) Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Int J Clin Exp Pathol 7(7):4239–4246PubMedPubMedCentral Zeng W et al (2014) Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Int J Clin Exp Pathol 7(7):4239–4246PubMedPubMedCentral
23.
Zurück zum Zitat Purroy N et al (2014) Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia 28(10):1993–2004CrossRefPubMed Purroy N et al (2014) Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia 28(10):1993–2004CrossRefPubMed
24.
Zurück zum Zitat Demchuk DV et al (2014) Synthesis and antiproliferative activity of conformationally restricted 1,2,3-triazole analogues of combretastatins in the sea urchin embryo model and against human cancer cell lines. Bioorg Med Chem 22(2):738–755CrossRefPubMed Demchuk DV et al (2014) Synthesis and antiproliferative activity of conformationally restricted 1,2,3-triazole analogues of combretastatins in the sea urchin embryo model and against human cancer cell lines. Bioorg Med Chem 22(2):738–755CrossRefPubMed
25.
Zurück zum Zitat Xu D et al (2008) Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells. Pharmazie 63(7):528–533PubMed Xu D et al (2008) Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells. Pharmazie 63(7):528–533PubMed
26.
Zurück zum Zitat Finlay D et al (2014) Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther 13(1):5–15CrossRefPubMed Finlay D et al (2014) Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther 13(1):5–15CrossRefPubMed
27.
Zurück zum Zitat Conte D et al (2006) Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol 26(2):699–708CrossRefPubMedPubMedCentral Conte D et al (2006) Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol 26(2):699–708CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Janji B et al (2010) The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner. J Cell Mol Med 14(6A):1264–1275CrossRefPubMed Janji B et al (2010) The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner. J Cell Mol Med 14(6A):1264–1275CrossRefPubMed
29.
Zurück zum Zitat Mizutani Y, Bonavida B (1993) Overcoming tnf-alpha and cddp resistance of a human ovarian-cancer cell-line (c30) by treatment with buthionine sulfoximine in combination with tnf-alpha and or cddp. Int J Oncol 3(2):229–235PubMed Mizutani Y, Bonavida B (1993) Overcoming tnf-alpha and cddp resistance of a human ovarian-cancer cell-line (c30) by treatment with buthionine sulfoximine in combination with tnf-alpha and or cddp. Int J Oncol 3(2):229–235PubMed
30.
Zurück zum Zitat Bharadwaj U et al (2011) Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10:106CrossRefPubMedPubMedCentral Bharadwaj U et al (2011) Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10:106CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Ferroni P et al (2012) Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Color Dis 27(12):1561–1567CrossRef Ferroni P et al (2012) Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Color Dis 27(12):1561–1567CrossRef
32.
33.
Zurück zum Zitat Giri DK, Aggarwal BB (1998) Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273(22):14008–14014CrossRefPubMed Giri DK, Aggarwal BB (1998) Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273(22):14008–14014CrossRefPubMed
34.
Zurück zum Zitat Jin HR et al (2012) Cryptopleurine targets NF-kappaB pathway, leading to inhibition of gene products associated with cell survival, proliferation, invasion, and angiogenesis. PLoS One 7(6):e40355CrossRefPubMedPubMedCentral Jin HR et al (2012) Cryptopleurine targets NF-kappaB pathway, leading to inhibition of gene products associated with cell survival, proliferation, invasion, and angiogenesis. PLoS One 7(6):e40355CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Pandey MK et al (2007) Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappa B signaling pathway. Blood 110(10):3517–3525CrossRefPubMedPubMedCentral Pandey MK et al (2007) Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappa B signaling pathway. Blood 110(10):3517–3525CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Hara K et al (2005) Synergistic enhancement of TRAIL- and tumor necrosis factor alpha-induced cell death by a phenoxazine derivative. Mol Cancer Ther 4(7):1121–1127CrossRefPubMed Hara K et al (2005) Synergistic enhancement of TRAIL- and tumor necrosis factor alpha-induced cell death by a phenoxazine derivative. Mol Cancer Ther 4(7):1121–1127CrossRefPubMed
37.
Zurück zum Zitat Van Antwerp DJ et al (1996) Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274(5288):787–789CrossRefPubMed Van Antwerp DJ et al (1996) Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274(5288):787–789CrossRefPubMed
38.
Zurück zum Zitat Cheung CH et al (2010) Correction: a cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy. Cancer Cell Int 10:43CrossRefPubMedPubMedCentral Cheung CH et al (2010) Correction: a cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy. Cancer Cell Int 10:43CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Totzke G, Schulze-Osthoff K, Janicke RU (2003) Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22(39):8021–8030CrossRefPubMed Totzke G, Schulze-Osthoff K, Janicke RU (2003) Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22(39):8021–8030CrossRefPubMed
40.
Zurück zum Zitat Mahal K et al (2015) Role of JNK and NF-kappaB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells. Cell Oncol (Dordr) 38(6):463–478CrossRef Mahal K et al (2015) Role of JNK and NF-kappaB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells. Cell Oncol (Dordr) 38(6):463–478CrossRef
41.
Zurück zum Zitat Mackenzie GG, Keen CL, Oteiza PI (2006) Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem 99(2):402–415CrossRefPubMed Mackenzie GG, Keen CL, Oteiza PI (2006) Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem 99(2):402–415CrossRefPubMed
42.
Zurück zum Zitat Jung YJ et al (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17(14):2115–2117CrossRefPubMed Jung YJ et al (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17(14):2115–2117CrossRefPubMed
43.
Zurück zum Zitat Cvetkovic I et al (2004) Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB. Cell Mol Life Sci 61(10):1167–1175CrossRefPubMed Cvetkovic I et al (2004) Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB. Cell Mol Life Sci 61(10):1167–1175CrossRefPubMed
44.
Metadaten
Titel
Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells
verfasst von
Jade K. Pollock
Lisa M. Greene
Seema M. Nathwani
Paula Kinsella
Niamh M. O’Boyle
Mary J. Meegan
Daniela M. Zisterer
Publikationsdatum
19.02.2018
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2018
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0543-z

Weitere Artikel der Ausgabe 4/2018

Investigational New Drugs 4/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.